Stockwinners Market Radar for October 17, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Netflix (NFLX) estimates that its latest megahit, "Squid Game," will create almost $900 million in value for the company, Bloomberg's Lucas Shaw reported, citing figures seen by the publication. In the case of "Squid Game," Netflix estimates that 89% of people who started the show watched at least 75 minutes - more than one episode - and 66% of viewers, or 87 million people, have finished the series in the first 23 days. All told, people have spent more than 1.4 billion hours watching the show, which was produced by closely held Siren Pictures. 2. The fast-growing e-commerce business of luxury retailer Saks Fifth Avenue is aiming to go public soon at a valuation roughly triple what it was pegged at earlier this year, The Wall Street Journal's Cara Lombardo reported. Saks is interviewing potential underwriters this week for an initial public offering that could take place in the first half of 2022 and targets a valuation of around $6 billion, the author noted, citing people familiar with the matter said. It was last valued at $2 billion in March. An IPO would be the second phase of a deal struck earlier this year that separated the e-commerce business from Saks' slower-growing bricks-and-mortar retail operations, the publication added. The move, meant to help fuel the digital unit's growth, prompted an activist investor to call for Macy's (M) to do the same last week. 3. Many investors have paid Dell Technologies little attention in recent years and it might be time to take a fresh look, Andrew Bary wrote in this week's edition of Barron's. Dell Technologies (DELL) is about to become much more attractive to investors as it prepares to spin off its valuable stake in software maker VMware (VMW) in early November, the author contended, arguing that Dell will emerge with a solid balance sheet and simpler structure. 4. Comcast (CMCSA) subsidiary Universal's "Halloween Kills" won the domestic box office with a $50.4M debut, the biggest horror opening of the pandemic era. The slasher movie also launched Friday on Universal's sister streaming service Peacock, which didn't disclose any viewership number for the pic. Overseas, "Halloween Kills" earned an estimated $5.5M from 20 markets for an early global cume of $55.9M. 5. MeiraGTx (MGTX), Chevron (CVX), Citigroup (C), Newmont (NEM), and British American Tobacco (BTI) saw positive mentions in this week's edition of Barron's.

17:05 EDT Biogen announces topline results from Phase 3 VALOR study of tofersen - Biogen announced topline results from its pivotal Phase 3 VALOR study of tofersen, an investigational antisense drug being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis. While tofersen did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, trends favoring tofersen were seen across multiple secondary and exploratory measures of biologic activity and clinical function. In addition, a pre-specified integration of data from VALOR and its ongoing open-label extension study reinforced these findings and showed that early tofersen initiation led to less decline across multiple measures of motor function, respiratory function, muscle strength, and quality of life in people with SOD1-ALS. Most adverse events in both VALOR and OLE were mild to moderate in severity, including procedural pain, headache, pain in extremity, fall and back pain. Biogen is actively engaging with regulators, the medical community, patient advocacy groups and other key stakeholders around the world to determine potential next steps. In light of the critical unmet need, Biogen will expand eligibility for its ongoing early access program to all people with SOD1-ALS, in countries where such programs are permitted by local regulations and future access may be secured. EAP programs enable patients to gain access to a medicine free of charge before the treatment is licensed commercially. If a clear path forward for tofersen is not established, or if another controlled trial is required by regulators, Biogen may revise or discontinue the EAP.